Epix CEO Kauffman resigns

The CEO of Epix Pharmaceuticals, Michael G. Kauffman, has resigned. The company's board of directors appointed Elkan Gamzu to serve as interim chief executive effective.

ArunA Biomedical announced that William T. Sharp has been named president and CEO.

Living Cell Technologies Ltd has appointed one of its directors, Dr Robert Caspari, as chief executive officer.

Horizon Therapeutics has appointed Timothy Walbert as its new president, CEO and member of the board.

AVI BioPharma named J. David Boyle chief financial officer and senior vice president. Boyle was previously the chief financial officer of Xoma Ltd. He succeeds Mark Webber, who is becoming AVI's general manager of finance and administration.

Osiris Therapeutics has appointed Richard Hunt as the chief financial officer.

West Pharmaceutical Services announced the appointment of Matthew T. Mullarkey to the position of chief operating officer.

Cardium Therapeutics has appointed Paul A. Foster as chief medical officer.

Insmed announced that Jim Miller, Ph.D. has joined the company as vice president of process development.

Tengion has named Mark Stejbach vice president, marketing and commercial planning.

Octagon Research Solutions has named Terek Peterson, MBA, as director, clinical programming.

Addex Pharmaceuticals has appointed Laurent Galibert head of the Addex Inflammation Business Unit.

Cytomedix announced that David F. Counts Ph.D., a medical researcher who discovered the company's anti-inflammatory peptide, CT-112, has been retained as a consultant to assist the company with the further development of the peptide.

Resverlogix has named Jan Gray to the board of directors.

Oramed Pharmaceuticals has named Dr. Harold Jacob to the board of directors.

Pluristem Therapeutics announced that Brian H. Annex, MD has accepted an appointment to the company's Scientific Advisory Board.

NanoViricides said that Kazuo Tsubota, MD, PhD, has agreed to join the company's Scientific Advisory Board.

Michael Marks was appointed to the board of Genesis Pharmaceuticals.

Human Genome Sciences announced that David P. Southwell has been appointed to the HGS board of directors.

PolyMedix has elected Dr. Richard Bank and Dr. Stefan Loren to the board of directors.